Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - Predictive Oncology Inc. | exh_321.htm |
| EX-31.2 - EXHIBIT 31.2 - Predictive Oncology Inc. | exh_312.htm |
| EX-31.1 - EXHIBIT 31.1 - Predictive Oncology Inc. | exh_311.htm |
| EX-23.2 - EXHIBIT 23.2 - Predictive Oncology Inc. | exh_232.htm |
| EX-21.1 - EXHIBIT 21.1 - Predictive Oncology Inc. | exh_211.htm |
| EX-4.29 - EXHIBIT 4.29 - Predictive Oncology Inc. | exh_429.htm |
| 10-K - FORM 10-K - Predictive Oncology Inc. | f10k_031521p.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements on Form S-1 (File No. 333-215005, 333-234366, 333-239207, 333-252584, and 333-252585) Form S-3 (File No. 333-213766, 333-221966, 333-228908, 333-234073, 333-235441, 333-237581, and 333-239851), Form S-4 (File No. 333-228031) and Form S-8 (File No. 333-169556, 333-175565, 333-186464, 333-188510, 333-198378, 333-213742, 333-216711, 333-230704, and 333-250149) of Predictive Oncology Inc. of our report dated March 15, 2021, relating to the consolidated financial statements, which report expresses an unqualified opinion on the consolidated financial statements for the year ended December 31, 2020, appearing herein.
| /s/ Baker Tilly US, LLP (formerly known as Baker Tilly Virchow Krause, LLP) | |
| Minneapolis, Minnesota | |
| March 15, 2021 |